Menu Search
Equities

TG Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NKB2:FRA

TG Therapeutics Inc

Actions
  • Price (EUR)23.24
  • Today's Change-1.05 / -4.30%
  • Shares traded100.00
  • 1 Year change-26.50%
  • Beta1.8771
Data delayed at least 15 minutes, as of Feb 06 2026 07:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

  • Revenue in USD (TTM)531.90m
  • Net income in USD447.47m
  • Incorporated1993
  • Employees374.00
  • Location
    TG Therapeutics Inc3020 Carrington Mill Blvd., Suite 475MORRISVILLE 27560-5435United StatesUSA
  • Phone+1 (212) 554-4484
  • Fax+1 (212) 554-4531
  • Websitehttps://www.tgtherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.